AJANTPHARM Ajanta Pharma Q2 FY27 results (Jul–Sep 2026) and concall
Ajanta delivered a strong Q2 FY27, with revenue up 33% to Rs. 1,794 crores and PAT up 49% to Rs. 388 crores. Every business grew, led by US generics (+41%), Africa Institution (+259%) and Africa branded generics (+41%). Management kept FY27 guidance unchanged: high-teens revenue growth and an EBITDA margin of about 27% ±100bps. This implicitly signals that H2 margins will step down to about 26% as US competition builds, institutional tenders normalize and R&D spending rises toward 5% of revenue. The balance sheet strengthened further, with ROCE at 41%, RONW at 31% and net cash of Rs. 574 crore
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q2 FY27: revenue up 135.7%, net profit up 49.2% against the same quarter last year.
| Line item | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 | Q2 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 4 | 11 | 14 | 14 | 20 +400% | 21 +91% | 25 +79% | 33 +136% |
| EBITDA | 321 | 297 | 351 | 328 | 382 +19% | 333 +12% | 424 +21% | 548 +67% |
| Net profit | 233 | 225 | 255 | 260 | 274 +18% | 267 +19% | 334 +31% | 388 +49% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
